Mineralys Therapeutics Inc (NASDAQ: MLYS) started the day on Thursday, with a price decrease of -6.28% at $33.13, before settling in for the price of $35.35 at the close. Taking a more long-term approach, MLYS posted a 52-week range of $8.24-$47.65.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -170.42%. Meanwhile, its Annual Earning per share during the time was -170.42%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 35.15%. This publicly-traded company’s shares outstanding now amounts to $78.97 million, simultaneously with a float of $56.37 million. The organization now has a market capitalization sitting at $2.62 billion. At the time of writing, stock’s 50-day Moving Average stood at $39.25, while the 200-day Moving Average is $25.52.
Mineralys Therapeutics Inc (MLYS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Mineralys Therapeutics Inc’s current insider ownership accounts for 28.77%, in contrast to 79.63% institutional ownership. According to the most recent insider trade that took place on Jan 05 ’26, this organization’s Chief Medical Officer sold 192,715 shares at the rate of 35.02, making the entire transaction reach 6,749,109 in total value, affecting insider ownership by 61,804. Preceding that transaction, on Jan 02 ’26, Company’s Chief Medical Officer sold 70,037 for 35.87, making the whole transaction’s value amount to 2,511,919. This particular insider is now the holder of 69,188 in total.
Mineralys Therapeutics Inc (MLYS) Earnings and Revenue Records
Mineralys Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 35.15% and is forecasted to reach -2.19 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.46% through the next 5 years, which can be compared against the -170.42% growth it accomplished over the previous five years trading on the market.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Let’s observe the current performance indicators for Mineralys Therapeutics Inc (MLYS). It’s Quick Ratio in the last reported quarter now stands at 25.50.
In the same vein, MLYS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.96, a figure that is expected to reach -0.52 in the next quarter, and analysts are predicting that it will be -2.19 at the market close of one year from today.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
If we take a close look at the recent performances of Mineralys Therapeutics Inc (NASDAQ: MLYS), its last 5-days Average volume was 1.31 million that shows progress from its year to date volume of 1.31 million. During the previous 9 days, stock’s Stochastic %D was recorded 26.56% While, its Average True Range was 20.73.
Raw Stochastic average of Mineralys Therapeutics Inc (MLYS) in the period of the previous 100 days is set at 56.51%, which indicates a major rise in contrast to 8.98% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.63 that was lower than 2.28 volatility it exhibited in the past 100-days period.
